Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective March 31, 2026, granting options to purchase an aggregate of 32,000 shares under its 2019 Inducement Equity Incentive Plan.
The options carry a 10-year term, an exercise price of $4.13 (closing price on March 31, 2026) and a four-year vesting schedule (25% after 12 months, then monthly over 36 months).
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q4 and full‑year 2025 results and a corporate update on March 17, 2026. Key items: 4WARD Phase 3 enrollment on track to complete in Q3 2026, a positive CHMP opinion for mavorixafor in WHIM syndrome, and a $253.0M cash position that management says funds operations through 2028.
Financials: 2025 product sales $6.5M, license revenue $28.6M, operating loss $86.9M, and net loss $79.2M for the year ended December 31, 2025.
X4 Pharmaceuticals (NASDAQ: XFOR) said management will join a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami. A live and archived webcast will be available on the company’s Investors site under Events and Presentations.
X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement equity awards effective February 27, 2026, granting options to purchase an aggregate of 24,000 shares to new employees under its 2019 Inducement Equity Incentive Plan.
The options have a 10-year term, an exercise price of $3.44 (closing price on February 27, 2026) and vest 25% after 12 months, then monthly over 36 months, subject to continued employment and plan terms; grants were approved by the compensation committee per Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (Nasdaq: XFOR) announced the EMA CHMP has issued a positive opinion recommending marketing authorization under exceptional circumstances for mavorixafor (XOLREMDI) to treat WHIM syndrome in the EU. The European Commission is expected to issue a final decision in Q2 2026.
CHMP support is based on the Phase 3 4WHIM trial showing statistically significant increases in ANC and ALC thresholds, ~40% reduction in total infection score, and a 60% reduction in annualized infection rate versus placebo. X4 has a commercialization license with Norgine and may receive up to €226 million plus escalating royalties.
X4 Pharmaceuticals (Nasdaq: XFOR) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11–12, 2026 in New York.
The company will hold a fireside chat on February 12 at 12:30 p.m. ET, offer one-on-one investor meetings, and provide a webcast and 30-day replay on its Investors Events and Presentations page.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective January 30, 2026, under its 2019 Inducement Equity Incentive Plan to new employees.
The awards total 20,000 options, each with a ten‑year term and an exercise price of $3.70 (closing price on January 30, 2026). Options vest over four years (25% after 12 months, then monthly over 36 months).
X4 Pharmaceuticals (Nasdaq: XFOR) announced that its management team will participate in the Guggenheim Second Annual Healthcare Innovation Conference in Boston on November 10–12, 2025. The company will host a fireside chat on November 10 at 8:30 a.m. ET and will be available for one-on-one investor meetings. A live webcast of the fireside chat will be available on the company’s Investors > Events and Presentations page, with a replay accessible for 30 days after the event. For more information, visit investors.x4pharma.com.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q3 2025 results and a corporate update focused on advancing the 4WARD Phase 3 trial of mavorixafor for chronic neutropenia. The company completed two financings totaling $240.3M and said cash runway now extends to the end of 2028, supporting trial completion, a potential sNDA filing and a possible 2028 launch if successful. Operational changes include a 50% workforce reduction (estimated $13M annualized savings), deprioritization of WHIM commercialization, promotion of John Volpone to COO, and an increased 4WARD enrollment target of 176 patients with completion expected in Q3 2026.
Q3 net product sales were $1.6M, Q3 net loss was $29.8M (EPS -$0.69), and cash, cash equivalents and short-term investments were $122.2M as of Sept 30, 2025.
X4 Pharmaceuticals (Nasdaq: XFOR) closed an underwritten public offering on October 27, 2025, selling 52,844,000 common shares including the full exercise of a 6,984,000-share underwriter option at $2.90 per share.
The company also issued pre-funded warrants for up to 700,000 shares at a public price of $2.899 each, exercisable immediately at $0.001 per share. Aggregate gross proceeds were approximately $155.3 million before underwriting discounts, commissions and offering expenses. Total shares outstanding after the offering were 79,214,708. Joint bookrunners were Leerink Partners, Stifel and Guggenheim Securities.